Keyphrases
Acute Leukemia
11%
Acute Lymphoblastic Leukemia
11%
Acute Myeloid Leukemia
27%
Adrenoleukodystrophy
5%
Allogeneic
8%
Allogeneic Bone Marrow Transplantation
7%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
64%
Allogeneic Transplantation
9%
B Cells
6%
Bone Marrow
14%
Bone Marrow Transplantation
21%
CD8+ T Cells
5%
Cell Therapy
13%
Chemotherapy
10%
Children's Oncology Group
8%
Chimeric Antigen Receptor T Cells (CAR-T)
5%
Chronic Myeloid Leukemia
6%
Clinical Outcomes
7%
Clinical Trials
11%
Conditioning Regimen
6%
Confidence Interval
25%
COVID-19
6%
Critically Ill children
6%
Cyclophosphamide
7%
Cytomegalovirus
6%
Disease-free Survival
6%
Electronic Health Records
7%
Embryonic Stem Cells
6%
Endothelial Cells
5%
Engraftment
10%
Epidermolysis Bullosa
10%
Fanconi Anemia
9%
First Complete Remission
7%
Fludarabine
6%
Graft-versus-host Disease (GvHD)
100%
Graft-versus-leukemia Effect
6%
Hazard Ratio
10%
Hematological Malignancies
9%
Hematopoietic Cell Transplant
9%
Hematopoietic Cell Transplantation
45%
Hematopoietic Cells
5%
Hematopoietic Stem Cell Transplantation
20%
Hematopoietic Stem Cells
12%
High Risk
8%
HLA Matching
8%
HLA-matched Donor
6%
Induced Pluripotent Stem Cells (iPSCs)
12%
Inflammation
6%
Interleukin-15 (IL-15)
8%
Interleukin-2
8%
Killer Cell Immunoglobulin-like Receptor
9%
Leukemia
9%
Leukemia Patients
6%
Lymphoma
7%
Marrow
8%
Marrow Transplantation
24%
Mesenchymal Stromal Cells
7%
Mouse Model
6%
Multiple Myeloma
5%
Myeloablative
7%
Myeloablative Conditioning
8%
Myelodysplastic Syndrome
9%
Myogenic Progenitors
6%
Natural Killer Cells
40%
Non-relapse Mortality
9%
Older Adults
6%
Ovarian Cancer
5%
Overall Survival
18%
Pediatric
11%
Pediatric Patients
7%
Peripheral Blood
6%
Phase II Trial
6%
Photosystem II
9%
Pretransplant
8%
Progression-free Survival
6%
Reduced-intensity Conditioning
15%
Regulatory T Cells
13%
Relapsed or Refractory
6%
Relative Risk
7%
Risk Factors
8%
Sickle Cell Disease
11%
Stem Cell Transplantation
5%
Stem Cell-derived
7%
Stem Cells
6%
Survivors
8%
T Cell Activation
5%
T Cells
22%
Tacrolimus
6%
Total Body Irradiation
6%
Transfusion
6%
Transplant Outcomes
10%
Transplantation
35%
Treatment-related Mortality
5%
Treg
13%
Tumor
9%
Umbilical Cord Blood
22%
Umbilical Cord Blood Transplantation
16%
United States
6%
Unrelated Donor
29%
Unrelated Donor Transplantation
8%
Immunology and Microbiology
Acute Graft Versus Host Disease
27%
Allele
6%
Allogeneic Hematopoietic Stem Cell Transplantation
9%
Allograft
13%
B Cell
12%
Blood Plasma
5%
Bone Marrow Transplantation
13%
CD34
5%
CD4
5%
Cell Function
7%
Cell Transplantation
55%
Chronic Graft Versus Host Disease
29%
Conditioning
25%
Cord Blood Stem Cell Transplantation
16%
Cyclophosphamide
8%
Cytokine
9%
Cytomegalovirus
7%
Cytotoxic T-Cell
6%
Disease Free Survival
5%
Engraftment
11%
Graft-Versus-Host Disease
56%
Hematopoietic Cell
73%
Hematopoietic Stem Cell Transplantation
17%
Human Leukocyte Antigen
5%
Immunotherapy
9%
In Vitro
11%
Infection
21%
Interleukin 15
5%
Interleukin 2
8%
Killer-Cell Immunoglobulin-Like Receptor
6%
Lineages
7%
Mesenchymal Stem Cell
8%
Myeloid
19%
Natural Killer Cell
42%
Neutrophil
7%
Overall Survival
14%
Platelet
6%
Regulatory T Cell
26%
Stem Cell
10%
T Cell
37%
T-Helper Cell
6%
Tacrolimus
6%
Umbilical Cord Blood
31%
Medicine and Dentistry
Acute Graft Versus Host Disease
13%
Acute Leukemia
9%
Acute Lymphoblastic Leukemia
12%
Acute Myeloid Leukemia
22%
Allogeneic Hematopoietic Stem Cell Transplantation
9%
Allograft
13%
B Cell
6%
Biological Marker
5%
Bone Marrow Transplantation
18%
Cancer
5%
Cell Therapy
13%
Cell Transplantation
56%
Chronic Graft Versus Host Disease
22%
Clinical Trial
12%
Conditioning
9%
Cord Blood
22%
Cord Blood Stem Cell Transplantation
9%
COVID-19
5%
Cyclophosphamide
5%
Disease Free Survival
5%
Diseases
31%
Engraftment
7%
Epidermolysis Bullosa Dystrophica
6%
Fanconi Anemia
7%
Graft Versus Host Reaction
30%
Hazard Ratio
10%
Hematologic Malignancy
6%
Hematopoietic Cell
73%
Hematopoietic Stem Cell Transplantation
20%
Hurler Syndrome
7%
Immunotherapy
6%
In Vitro
7%
Induced Pluripotent Stem Cell
5%
Infection
11%
Infusion
5%
Leukemia
11%
Lung
6%
Malignant Neoplasm
9%
Mesenchymal Stem Cell
5%
Multiple Myeloma
5%
Myelodysplastic Syndrome
9%
Natural Killer Cell
16%
Neoplasm
9%
Oncology
9%
Ovarian Cancer
6%
Overall Survival
19%
Pediatrics
17%
Platelet
7%
Progression Free Survival
6%
Reduced Intensity Conditioning
9%
Regulatory T Cell
7%
Sickle-Cell Disease
9%
Stem Cell
8%
T Cell
18%
Whole Body Radiation
5%